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Podocyte injury is a significant contributor to proteinuria and
glomerulosclerosis. Recent studies have shown a
renoprotective effect of erythropoietin (EPO) during ischemic
kidney disease. In this study, we examine mechanisms by
which a long acting recombinant EPO analog, darbepoetin,
may confer renoprotection in the puromycin
aminonucleoside-induced model of nephrotic syndrome.
Darbepoetin decreased the proteinuria of rats treated with
puromycin. This protective effect was correlated with the
immunohistochemical disappearance of the podocyte injury
markers desmin and the immune costimulator molecule B7.1
with the reappearance of nephrin expression in the slit
diaphragm. Podocyte foot process retraction and effacement
along with actin filament rearrangement, determined by
electron microscopy, were all reversed by darbepoetin
treatment. The protective effects were confirmed in
puromycin-induced nephrotic rats that had been
hemodiluted to normal hematocrit levels. Furthermore,
puromycin treatment of rat podocytes in culture caused actin
cytoskeletal reorganization along with deranged nephrin
distribution. All these effects in vitro were reversed by
darbepoetin. Our study demonstrates that darbepoetin
treatment ameliorates podocyte injury and decreases
proteinuria by a direct effect on podocytes. This may be
accomplished by maintenance of the actin cytoskeleton and
nephrin expression.
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The terminally differentiated podocyte, also called glomeru-
lar visceral epithelial cell, is a highly specialized cell.
The clinical signature of podocyte injury is proteinuria,
and podocyte loss in association with the inability to replace
those lost because of a lack of proliferation results in
glomerulosclerosis.1,2 The characteristic morphological
changes observed during the development of proteinuria
occur in podocytes. Foot process effacement is closely
correlated with the development of proteinuria.3,4 These
shape changes in the podocytes are also associated with
rearrangement of actin cytoskeleton.5,6 The expression of
nephrin, which is a major component of slit diaphragms, also
decreases in a variety of disease conditions characterized by
proteinuria.7–9
Anemia is a common complication of chronic kidney
disease. Development of recombinant erythropoietin (EPO)
as a therapeutic reagent is one of the major advances in the
management of patients with chronic kidney failure over the
past several decades.10 In addition to correction of anemia,
accumulating evidence indicates that EPO has effects outside
of the hematopoietic system and serves as a novel
cytoprotective agent in both neuronal and vascular sys-
tems.11,12
Previous studies focused on a renoprotective effect of EPO
in ischemic kidney diseases (reviewed by Sharples and
Yaqoob13 Chatterjee14). Important mechanisms of renopro-
tection by EPO include antiapoptotic effects and recruitment
of endothelial precursor cells.15,16 However, demonstration of
cytoprotection of EPO in a variety of organs stimulated us to
study a therapeutic potential of EPO in podocyte injury. We
employed the long-acting recombinant human EPO analo-
gue, darbepoetin alpha, in a model of nephrotic syndrome
induced by puromycin aminonucleoside (PAN). Darbopoie-
tin is an analogue of recombinant human EPO with increased
glycosylation that stimulates erythropoiesis via the same
mechanism as the native hormone and has a greater in vivo
metabolic stability. Injection of PAN causes podocyte injury,
for example, actin cytoskeletal disorganization, reduced
expression of molecular components of slit diaphragm such
as nephrin, and foot process effacement, leading to induction
of a well-described model of proteinuria.
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RESULTS
Darbepoetin ameliorates proteinuria in PAN
PAN induced massive proteinuria on day 7, which
was significantly suppressed by darbepoietin (Table 1).
Darbepoetin treatment at this dose increased the
levels of hematocrit and hemoglobin (Hb), whereas it
did not induce significant changes in blood urea nitrogen
levels.
Histological and immunohistochemical analysis revealed
protection of podocytes by darbepoetin. Periodic acid-Schiff
staining of kidney samples from experimental animals
showed no abnormal findings in glomeruli, whereas the
tubulointerstitial compartment showed tubular injury and
inflammation, reflecting massive proteinuria (data not
shown). Immunohistochemical studies showed upregulation
of desmin, a marker of podocyte injury, in PAN rats (Figure
1a–c). In the normal kidney, anti-desmin antibody weakly
reacted with the mesangial cells, whereas staining in the
podocytes was negative. In PAN rats, conspicuously enhanced
staining for desmin was seen in the podocytes, whereas
darbepoetin treatment resulted in a decrease in desmin
expression by the podocytes. Expression of B7-1, another
indicator of podocyte damage, was also upregulated in PAN
animals (Figure 2a–c). Darbepoetin treatment also amelio-
rated B7-1 expression in podocytes. Immunostaining of a
podocyte-associated protein, nephrin, yielded an epithelial-
like pattern in glomeruli, whereas the innermost glomerular
tuft areas remained negative, in normal rats. Induction of
PAN resulted in a less intense reactivity at the epithelial
aspect, whereas darbepoetin treatment recovered nephrin
staining in podocytes (Figure 3a–c). Dramatic mitigation of
the abnormal staining profile of desmin and nephrin in
podocytes was confirmed by semiquantitative analyses
(Figure 1d, 3d).
Electron microscopic analysis showed swollen podocytes
in PAN. The foot processes of podocytes retracted and effaced
(Figure 4), resulting in displacement and disruption of the
specialized slit diaphragms that span the filtration slits
between foot processes. Foot process fusion was often
associated with detachment from the underlying glomerular
basement membrane. These are the characteristic ultrastruc-
tural changes observed during the development of nephrotic
Table 1 | Physiological parameters of experimental animals at
day 7
Vehicle-treated PAN
rats
Darbepoietin-treated
PAN rats
Proteinuria (mg/day) 184.5 (135.6–210.0) 58.8 (13.0–110.3)a
BUN (mg/dl) 15.5 (12.0–35.3) 13.5 (12.0–17.8)
Hematocrit (%) 41.0 (36.8–42.5) 51.5 (50.0–54.0)a
Hemoglobin (g/dl) 13.9 (12.5–14.5) 17.5 (17.0–18.4)a
BUN, blood urea nitrogen; IQR, interquartile range; PAN, puromycin aminonucleo-
side.
Data was shown by median and IQR.
aPo0.01 versus vehicle treated.
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Figure 1 | Expression of desmin. (a) Desmin was markedly
upregulated in podocytes of PAN rats treated with vehicle.
(b) Upregulation of desmin was ameliorated by treatment with
darbepoietin. (c) Expression of desmin was not observed in
podocytes of control rats. (d) Semiquantitative analysis of desmin
confirmed mitigation of desmin expression by darbepoietin. Mean
values7s.e.m. are presented (n¼ 25 glomeruli per group), ##Po0.01
versus vehicle treated.
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Figure 2 | Expression of B7-1. (a) B7-1 was markedly upregulated in
podocytes of PAN rats treated with vehicle. (b) Upregulation of B7-1
was ameliorated by treatment with darbepoietin. (c) Expression of
B7-1 was not observed in podocytes of control rats.
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syndrome. These alterations were highly diffuse and were
closely associated with dramatic rearrangements of the actin
filaments in foot processes. These changes were ameliorated
in darbepoetin-treated rats.
Darbepoetin suppresses derangements of actin and nephrin
in cultured podocytes
In order to elucidate a mechanism of darbepoetin-mediated
improvement in the glomerular barrier function, we
employed cultured rat podocytes. F-actin staining
revealed a characteristic flattened phenotype with numerous
cell processes and prominent central actin stress fibers in
cultured podocytes before treatment (Figure 5c). Treatment
of podocytes with PAN resulted in a progressive retraction
of processes, disruption of the actin stress fibers, and
subsequent detachment of some podocytes from the under-
lying substrate, whereas darbepoetin suppressed the actin
cytoskeletal reorganization evoked by PAN (Figure 5a and b).
Protection against actin cytoskeletal reorganization by
darbepoetin treatment tended to be observed in a
dose-dependent manner (Figure 6). PAN treatment also
induced a reduction of nephrin expression in cultured
podocytes, however, darbepoetin treatment markedly re-
stored (Figure 7). Moreover, in order to elucidate
the possibility that protective effects of darbepoetin had
been through receptor tyrosine kinases (RTKs), we examine
whether the beneficial effects could be perturbed by RTK
inhibitors for example PD153035 for epidermal growth factor
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Figure 3 | Expression of nephrin in rat kidney. (a) PAN rats treated
with vehicle demonstrated a discontinuous pattern of nephrin
with diminished intensity in podocytes. (b) Treatment with
darbepoietin restored the continuous pattern of nephrin expression.
(c) Control rats showed the linear-like pattern of nephrin.
(d) Semiquantitative analysis of nephrin confirmed mitigation of
nephrin expression by darbepoietin. Mean values7s.e.m. are
presented (n¼ 25 glomeruli per group) ##Po0.01 versus vehicle
treated.
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Figure 4 | Electron microscopic analysis. (a) Electron microscopic
analysis showed swollen podocytes with diffuse foot process
effacement in vehicle-treated PAN rats. Original magnification
 9000  20000. (b) The injury of podocytes and the slit
diaphragm was mitigated by treatment with darbepoetin. Original
magnification  9000  20000.
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Figure 5 | Changes of the actin cytoskeleton in cultured
podocytes. (a) PAN treatment altered the pattern of actin fibers in
cultured podocytes, (b) whereas darbepoetin restored the normal
actin cytoskeletal organization. (c) Control podocytes showed the
normal pattern of actin fibers.
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receptor and SU1498 for vascular endothelial growth factor
receptor. As shown in Figure 8, actin cytoskeletal reorganiza-
tion was protected by darbepoetin treatment even in the
presence of the RTK inhibitors.
Darbepoetin ameliorates proteinuria in PAN rats with
hemodilution
In order to evaluate a possible contribution of polycythemia
to a beneficial effect by darbepoetin, we performed weekly
hemodilution in darbepoietin-treated rats. As shown in
Table 2, hemodilution kept the levels of hematocrit and Hb of
darbepoietin-treated animals within the normal range.
However, massive proteinuria was significantly suppressed
by darbepoietin on days 7 and 14 even in these hemodiluted
rats, whereas it did not induce significant changes in blood
urea nitrogen levels (29.3 interquartile range (26.6–31.1)
versus 24.5 interquartile range (22.4–29.5) mg/dl, on day 14).
EPO-R expression in rat podocytes
To confirm the localization of EPO receptor (EPO-R) in rat
glomeruli, we first performed immunohistochemical analysis
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Figure 6 | Dose-dependent effects of darbepoetin on
reorganization of the actin cytoskeleton. Disruptions of the actin
stress fibers with PAN treatment were ameliorated by darbepoein in a
dose-dependent manner. Podocytes were treated with darbepoetin
in (a) 0 U/ml, (b) 0.2 U/ml, (c) 2.0 U/ml, (d) 20.0 U/ml.
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Figure 7 | Changes of nephrin expression in cultured podocytes.
PAN treatment also induced a reduction of nephrin expression in
cultured podocytes, which were markedly restored by darbepoetin.
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Figure 8 | The effects of darbepoetin on reorganization of the
actin cytoskeleton in the presence of RTK inhibitors in cultured
podocytes. Disruption of the actin stress fibers with PAN treatment
was ameliorated by darbepoetin even in the presence of RTK
inhibitors. Podocytes were treated with (a) vehicle, (b) darbepoetin,
(c) darbepoetin and 10mM of PD153035, darbepoetin and (d) 10 mM of
SU1498.
Table 2 | Physiological parameters of experimental animals with hemodilution
Vehicle-treated PAN rats Darbepoietin-treated PAN rats Vehicle-treated PAN rats Darbepoietin-treated PAN rats
Measuring Point Day 7 Day 7 Day 14 Day 14
Proteinuria (mg/day) 175.7 (157.1–198.7) 11.8 (3.7–82.3)a 212.5 (174.8–218.3) 21.1 (0.49–65.0)a
Hematocrit (%) 39.0 (35.0–40.0) 39.5 (38.3–43.0) 38.0 (37.0–40.0) 36.5 (32.8–37.8)
Hemoglobin (g/dl) 13.3 (11.9–13.6) 13.5 (13.0–14.7) 12.9 (12.6–13.6) 12.4 (11.2–12.8)
IQR, interquartile range; PAN, puromycin aminonucleoside.
Data was shown by median and IQR.
aPo0.01 versus vehicle treated.
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in rat kidney tissues. We observed EPO-R expression in
podocytes as well as in tubular cells (Figure 9a). In addition,
reverse transcriptase-polymerase chain reaction (RT-PCR)
and immunoblot analysis also demonstrated EPO-R expres-
sion in cultured rat podocytes (Figure 9c and d). Both data
indicated the expression of EPO-R in rat podocytes.
TUNEL staining
To investigate whether the protective effect of darbepoetin in
the podocytes was due to amelioration of apoptosis in
addition to the cytoskeletal protection, we performed
terminal deoxynucleotidyl transferase (TdT)-mediated deox-
yuridin triphosphate (dUTP) nick end labeling (TUNEL)
staining in both kidneys of the experimental rats and cultured
podocytes. As shown in Figure 10, no positive signals were
present in the glomeruli of vehicle- and darbepoetin-treated
rats. Studies utilizing cultured podocytes also demonstrated
no significant difference between vehicle- and darbepoetin-
treated groups. Taken together, these results suggest that
podocyte apoptosis is unlikely to contribute to the beneficial
effects by darbepoietin in our experimental conditions.
DISCUSSION
The question addressed by the present study was whether
darbepoetin has a direct action on podocytes resulting in
protection from and/or amelioration of injury. Our study
demonstrated that darbepoetin reduced urinary protein
excretion in PAN rats by protection of podocytes. Protection
of podocytes by darbepoietin was demonstrated by electron
microscopic analysis as well as two established podocyte
injury markers, that is desmin17 and B7-1.18
Although it is plausible to speculate that an increase in
oxygen-carrying capacity might improve structures and
functions of podocytes, it is an unlikely mechanism in
PAN. Injury of podocytes in this model is mediated by
oxidative stress and direct insults induced by PAN,19,20 but no
previous reports suggested a role of hypoxia in podocyte
injury of PAN. In order to rule out a possible contribution of
an increase in hematocrit, we conducted hemodilution in
darbepoetin-treated PAN rats. We observed equivalent
protective effects of darbepoetin even when hematocrit
between vehicle- and darbepoetin-treated rats was kept at
the same levels.
To elucidate the mechanisms of protective action of EPO
in PAN, we performed in vitro study using immortalized rat
podocytes. The major finding in our in vitro study was that
EPO protected the disruption of actin cytoskeleton and the
reduction of nephrin caused by PAN.
A well-developed actin cytoskeletal structure plays a
critical role in the maintenance of podocyte foot process
architecture and filtration barrier function. Pathogenic
stimuli such as PAN cause actin cytoskeletal reorganiza-
tion.5,21 Nephrin, a critical component of the slit diaphragm
for maintaining the barrier function,22 is coupled to the
podocyte’s actin cytoskeleton, and derangement of the actin
cytoskeleton is proposed to be the common pathway leading
to foot process effacement in podocytes.23 Previous reports
showed a decrease in nephrin expression in PAN.24,25
Mounting evidence has demonstrated that PAN induces
actin cytoskeleton reorganization, which can lead to struc-
tural change of podocytes and the leak of protein through slit
diaphragm. However, the precise mechanisms of this
deleterious effect have remained to be fully understood.
Previous reports showed that reagents such as fluvastatin,
dexamethasone, and an inhibitor of p38 MAPK have
protective effects on actin disruption induced by PAN.26–28
In the current study, we newly demonstrated that the long-
acting recombinant human EPO analogue, darbepoetin
alpha, prevented the change of actin cytoskeleton and the
decrease of nephrin protein, whereas RTK inhibitors did not
alter the protective effects of darbepoetin in vitro, suggesting
that the beneficial effects observed in vivo may be due to the
prevention of these changes through the direct action of EPO
on podocytes.
Previous immunohistochemical and in situ hybridization
studies demonstrated expression of EPO-R in podocytes in
addition to tubular epithelial cells and glomerular endoca-
pillary cells.29 Our immunohistochemical, reverse transcrip-
tase-PCR and immunoblot analyses also showed the
expression of EPO-R in podocyte. EPO and EPO-R prevent
apoptosis and cellular inflammation through a series of
pathways that originate with the binding of EPO to the EPO-
R to activate Janus-tyrosine kinase 2, phosphoinositide 3
kinase, and protein kinase B (Akt).30,31 It is noteworthy that
several reports showed the direct interaction of Akt and actin.
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Figure 9 | EPO-R expression in rat podocytes. (a) Expression
of EPO-R in vivo was observed in rat podocytes. Arrows indicate
representative EPO-R-positive podocyte staining.
(b) Immunohistochemical staining was abolished without the
first antinephrin antibody. (c) Expression of EPO-R in cultured rat
podocytes was confirmed by reverse transcriptase-PCR analysis.
Lane1: primer set 1, lane2: primer set 2, lane 3: primer set 1 without
cDNA template. Predicted amplification size was 200 bp.
(d) Immunoblot analysis was carried out in cultured rat podocytes
with anti-EPO-R (lane 1) and without anti-EPO-R antibody (lane 2).
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Two groups revealed that the major protein observed in Akt
co-immunoprecipitates was the actin cytoskeleton and
growth factor such as platelet-derived growth factor triggers
an increase in the amount of Akt association with the actin
cytoskeleton.32,33 In chicken embryo fibroblast, phosphoino-
sitide 3 kinase activation via Akt is sufficient for actin
filament remodeling.34 Meanwhile, it was also reported that
Akt activation diminished cellular apoptosis in some types of
kidney cells, that is glomerular endothelial cells and epithelial
cells.15 However, our TUNEL-staining studies suggested that
anti-apoptosis effects of Akt were not involved in the
protective effects of darbepoetin on podocytes in our
experimental conditions. Although direct interaction of Akt
and actin may be involved in the beneficial mechanism of
EPO in podocytes, further elucidation of the EPO-mediated
signal transduction pathway in podocytes is necessary.
The first evidence of non-hematopoietic effect by EPO was
shown in the study demonstrating that infusion of EPO into
the lateral ventricles of gerbils prevented ischemia-induced
learning disability and rescued hippocampal CA1 neurons
from lethal ischemic damage.35 Subsequent studies showed
beneficial effects of EPO in the brain, heart, and kidney.36
Recently developed EPO without hematopoiesis, carbamy-
lated EPO, was effective without an increase in Hb levels in a
model of cerebral infarction37 as well as myocardial
infarction.38 Previous studies showed reduction of protei-
nuria by EPO and darbepoetin in the remnant kidney
model.15,39 Anti-proteinuric effects of EPO and darbepoetin
in these studies may be, at least in part, attributed to direct
protection of podocytes.
Some clinical studies showed renoprotective effects of
EPO in human chronic kidney disease patients. Kuriyama
et al.40 were the first to raise the possibility that EPO therapy
might actually delay progression of kidney disease. Other
studies also found stabilization of renal function by EPO
treatment.41–44 Although the beneficial effects observed in
these studies can be attributed to improvement of chronic
hypoxia in the tubulointerstitial compartment,45 our current
study suggested that direct cytoprotection of EPO on
intrinsic renal cells may also participate.
The dose of darbepoetin we used in this study was
relatively more than those employed clinically in human
chronic kidney disease patients (45 mg every-other-week per
person).46 Our results indicated that a supraphysiological
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Figure 10 | Detection of apoptosis by TUNEL staining. (a–c) Representative pictures of the kidneys. (a) Positive control was generated
by TACS-Nuclease treatment before TdT labeling. No TUNEL-positive cells were observed in glomeruli of (b) vehicle- and
(c) darbepoetin-treated animals. (d–g) Representative pictures of the cultured podocytes. (d) Positive control was generated by
TACS-Nuclease treatment before TdT labeling. A small number of TUNEL-positive cells were observed both in (e) vehicle- and
(f) darbepoetin-treated groups. (g) However, we did not observe significant difference in the number in TUNEL-positive cells in 10
randomly selected fields.
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dose of EPO was necessary in order to see a protective effect
on podocytes, which may limit the actual clinical application.
However, this dose was comparable to those used in previous
experimental studies.47,48 Larger doses of darbepoetin has
also been used in some clinical situations such as post-
myocardial infarction.49 Calculation utilizing the suggested
conversion index (epoietin alfa dose/200¼ darbepoetin dose)
also suggested that the dose of darbepoetin we employed in
this study was comparable to those of EPO used in many
previous studies.14
In conclusion, we demonstrated that darbepoietin pro-
tected the kidney against PAN. Darbepoietin treatment
ameliorated podocyte injury and reduced proteinuria. In
vitro experiments utilizing rat podocytes showed that
darbepoietin protected the disruption of actin cytoskeleton
and the reduction of nephrin. Our studies suggested that
darbepoietin may provide direct protection on podocytes, the
major culprit accounting for proteinuria.
MATERIALS AND METHODS
Chemicals
PAN was purchased from Sigma (St Louis, MO, USA). Alexa488
phalloidin was purchased from Invitrogen (Eugene, OR, USA). The
inhibitors, PD153035, and SU1498 were purchased from Calbio-
chem (San Diego, CA, USA).
Animal experimental design
Male Wistar rats that weighed 150–180 g were purchased from
Nihon Seibutsu Zairyo Center (Tokyo, Japan). All animal proce-
dures conducted were in accordance with the guidelines for the care
and use of laboratory animals approved by University of Tokyo
School of Medicine. Rats were divided into PAN and darbepoetin-
treated PAN groups (n¼ 6 for each). PAN was induced by a single
intravenous injection of PAN (50 mg/kg body weight). Darbepoetin
(30mg/kg) was administered subcutaneously 4 h before induction of
the disease.
On day 7, urine was collected using a metabolic cage, followed by
killing under ether anesthesia. Blood urea nitrogen, hematocrit, and
Hb were measured utilizing i-STAT (Abbott, East Windsor, NJ,
USA).
For the hemodilution study, rats were divided into PAN and
darbepoetin-treated PAN groups (n¼ 8 for each). Four milliliter of
blood was withdrawn from rats in the group of darbepoetin
injection. PAN was induced by a single intravenous injection of PAN
(50 mg/kg body weight). Darbepoetin (30 mg/kg) was administered
once a week subcutaneously 4 h after hemodilution. On days 7 and
14, urinary protein, blood urea nitrogen, hematocrit, and Hb were
measured.
Histology and immunohistochemistry
Kidneys were fixed in 10% neutralized formalin or Methyl Carnoy’s
solution after removal. They were then processed, embedded in
paraffin, and cut into 3 mm thickness sections that were stained with
periodic acid-Schiff reagent. For immunohistochemical analysis,
sections were incubated with primary antibodies. Anti-desmin
antibody, D33, was purchased from DAKO Cytomation (Kyoto,
Japan), anti-rat B7-1 from BD Pharmingen (San Diego, CA, USA),
anti-EPO-R antibody was purchased from Santa Cruz Biotechnol-
ogy (Santa Cruz, CA, USA). Immunostaining with the anti-nephrin
antibody was performed as reported previously.50 For B7-1 and
EPO-R, sections were processed with Vectastain ABC reagent
(Vector Lab, Burlingame, CA, USA).
After 3 h incubation at room temperature with the primary
antibody, the sections were incubated with biotinylated secondary
antibodies for 1 h, followed by 30-min incubation with horseradish
peroxidase-conjugated avidin D (Vector Lab). Color was developed
by incubation with diaminobenzidine (Wako Pure Chemical
Industries, Tokyo, Japan) and hydrogen peroxide and the sections
were counterstained with Mayer’s hematoxyline (Wako Pure
Chemical Industries, Tokyo, Japan).
For semiquantitative immunohistochemical analysis, 25 glomer-
uli were selected randomly in each animal and two investigators
independently did a blinded immunohistochemical image analysis.
The degree of glomerular staining was graded according to the
positively stained glomerular area expressed as a percentage of total
area: 0, no lesions; 1þ , 1–25%; 2þ , 5–50%; 3þ , 50–75%; 4þ ,
75–100%. An overall staining score per animal was obtained by
multiplying each score (0 to 4þ ) with the percentage of glomeruli
displaying the same degree of positive staining and summing these
scores.
Electron microscopic analysis
Tissues were fixed with 2.5% glutaraldehyde in phosphate buffer
(pH 7.4), postfixed with 1% osmium tetroxide, dehydrated, and
embedded in Epon 812 (Okenshoji, Tokyo, Japan). Ultrathin
sections were stained with uranyl acetate and lead citrate and were
then examined with a Hitachi H7100 electron microscope (Hitachi,
Yokohama, Japan).
Culture of temperature-sensitive immortalized podocytes
We employed cultured immortalized rat podocytes. Immortalized
rat podocyte cell lines were originally established by Dr Hidetake
Kurihara (Juntendo University School of Medicine, Tokyo, Japan).
The Cell line, 2DNA1D7, was isolated from decapsulated glomeruli
of tsA58 transgenic rats as described previously.51 Experiments were
performed, growth-restricted, conditionally immortalized rat podo-
cytes. Under these conditions, podocytes are fully differentiated and
quiescent, resembling the in vivo phenotype. Cells were grown in
Dulbecco’s modified Eagle’s medium/F-12 media containing 10%
fetal bovine serum (Gemini Bio-Products, Woodland, CA, USA),
penicillin (100 U/ml), streptomycin (100 mg/ml), 0.1% Insulin-
Trans-Cel-X (Gibco BioChemical, Grand Island, NY, USA). In order
to passage cells, podocytes were grown under ‘growth permissive’
conditions (331C). In order for podocytes to acquire a differentiated
and quiescent phenotype, cells were grown under ‘restrictive
conditions’ at 371C in 95% air/5% CO2 for more than 4 days.
For immunofluorescence, cultured podocytes were grown on
chamber slides. Darbepoetin (2 U/ml) was added to the media
before addition of PAN at the concentration of 50 mg/ml. After 48 h,
cells were fixed and permeabilized with 0.1% Triton X-100. After
being washed, cells were labeled with Alexa400-phalloidin.
For immunoblotting, cultured podocytes were passed onto
chamber slides and were allowed to adhere and spread. Darbepoetin
(2 U/ml) was added to the media before addition of PAN at the
concentration of 50 mg/ml. After 48 h, 30 mg of whole extract from
cultured podocytes was separated by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis under reducing conditions and
electrophoretically transferred to nylon membrane. The membrane
was incubated with the anti-nephrin or anti-EPO-R antibody.
Horseradish peroxidase-conjugated anti-rabbit immunoglobulin G
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was used as the secondary antibody. Immunoreactive protein was
visualized by the chemiluminescence protocol (ECL, Amersham,
Arlington Heights, IL, USA).
Reverse transcriptase-PCR analysis
To elucidate expression of EPO-R in the cultured podocytes, 1 mg
total RNA was converted to cDNA. cDNA was amplified by two sets
of PCR primers that target different regions of rat EPO-R gene. In
the first set of primers, oligonecleotides consisting of (forward 5_-
TCCGGCATCTCAACAGATTAC-3_ and reverse 5_-AGGGCTTT
AAATATGGCCTCA-3_) were synthesized. In the second set of
primers, oligonecleotides consisting of (forward 5_-TAGACCCTGC
GACTATGGATG-3_ and reverse 5_-ATCGGACACCACAAGGTA
CAG-3_) were synthesized. After an initial denaturation step at
951C for 2 min, 30 cycles of PCR amplification (951C, 20 s; 551C,
30 s; 731C, 1 min) were performed. Predicted size of PCR
amplification was designed to 200 bp. PCR amplification without
cDNA served as a negative control.
TUNEL staining
To detect and quantify apoptotic cells, TUNEL method was
performed using In situ Apoptosis Detection Kit (Trevigen,
Gaithersburg, MD, USA). Kidneys were fixed in Methyl Carnoy’s
solution after removal and were embedded in paraffin. Cultured
podocytes were fixed with 4% paraformaldehyde. To generate
positive controls, samples were treated with TACS-Nuclease before
terminal deoxynucleotidyl transferase (TdT) labeling.
Regarding the cultured podocytes, two investigators indepen-
dently counted apoptotic (TUNEL-positive) cells in 10 randomly
selected fields with  200 magnification.
Statistical analyses
Differences between the darbepoetin and vehicle-treated groups
were evaluated with the unpaired Student’s t-test. Nonparametric
data, including the histological scores, were analyzed by Man-
n–Whitney test. Values were considered significant if Po0.05.
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